Diagnostics in Focus: Accelerating Access for Priority Diseases in Africa

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Diagnostic Microbiology and Infectious Disease".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 545

Special Issue Editors


E-Mail Website
Guest Editor
Department of Clinical Research, London School of Hygiene and Tropical Medicine (LSHTM), London WC1E 7HT, UK
Interests: diagnostic development; evaluation; regulation; policy development; uptake

E-Mail Website
Guest Editor
Global Health Impact Group, Atlanta, GA, USA
Interests: molecular diagnostics

E-Mail Website
Guest Editor
Africa Centres for Disease Control and Prevention (Africa CDC), Haile Garment Square, Addis Ababa, Ethiopia
Interests: diagnostic development; evaluation; regulation; policy development; uptake

Special Issue Information

Dear Colleagues,

Africa CDC has published a list of priority epidemic-prone diseases in Africa. Any of the pathogens can cause epidemics or pandemics. Diagnostics are crucial in the preparedness and response for outbreaks. There is limited availability and accessibility of diagnostics for Africa priority diseases. This poses a huge challenge to make diagnostic tests available within 100 days of an outbreak.

Africa CDC has identified the top five priority pathogens that cause frequent outbreaks in the continent. These include dengue, cholera, mpox, measles and bacterial meningitis. To ensure diagnostics are available for these pathogens, there is need to establish mechanisms that can reduce bottlenecks and accelerate the introduction of diagnostics for use in public health systems

The Africa CDC Diagnostic Advisory Committee (DAC) was established as a continental mechanism to accelerate diagnostics by facilitating the development, evaluation, regulatory harmonization, policy development and uptake by countries. The DAC produces a list of diagnostic tests that can be considered for evaluation, regulatory harmonization and eventual uptake and use in countries. The development of this list requires a systematic process of reviewing the literature and conducting stakeholder engagement.

In this series, we present the priority listing of diagnostic tests for the top five epidemic prone diseases and outline key considerations to facilitate the development, evaluation, registration and uptake of the tools by African countries.

Prof. Dr. Rosanna Peeling
Dr. Debi Boeras
Dr. Nicaise Ndembi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diagnostics
  • epidemic-prone diseases
  • outbreak preparedness and response

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 472 KiB  
Communication
LAMPOX: A Portable and Rapid Molecular Diagnostic Assay for the Epidemic Clade IIb Mpox Virus Detection
by Anna Rosa Garbuglia, Mallory Draye, Silvia Pauciullo, Daniele Lapa, Eliana Specchiarello, Florence Nazé and Pascal Mertens
Diagnostics 2025, 15(15), 1959; https://doi.org/10.3390/diagnostics15151959 - 4 Aug 2025
Viewed by 436
Abstract
The global spread of Mpox virus (MPXV) underscores the urgent need for rapid, field-deployable diagnostic tools, especially in low-resource settings. We evaluated a loop-mediated isothermal amplification (LAMP) assay, termed LAMPOX, developed by Coris BioConcept. The assay was tested in three formats—two liquid versions [...] Read more.
The global spread of Mpox virus (MPXV) underscores the urgent need for rapid, field-deployable diagnostic tools, especially in low-resource settings. We evaluated a loop-mediated isothermal amplification (LAMP) assay, termed LAMPOX, developed by Coris BioConcept. The assay was tested in three formats—two liquid versions and a dried, ready-to-use version—targeting only the ORF F3L (Liquid V1) or both the ORF F3L and N4R (Liquid V2 and dried) genomic regions. Analytical sensitivity and specificity were assessed using 60 clinical samples from confirmed MPXV-positive patients. Sensitivity on clinical samples was 81.7% for Liquid V1 and 88.3% for Liquid V2. The dried LAMPOX assay demonstrated a sensitivity of 88.3% and a specificity of 100% in a panel of 112 negative controls, with most positive samples detected in under 7 min. Additionally, a simplified sample lysis protocol was developed to facilitate point-of-care use. While this method showed slightly reduced sensitivity compared to standard DNA extraction, it proved effective for samples with higher viral loads. The dried format offers key advantages, including ambient-temperature stability and minimal equipment needs, making it suitable for point-of-care testing. These findings support LAMPOX as a promising tool for rapid MPXV detection during outbreaks, especially in resource-limited settings where traditional PCR is impractical. Full article
Show Figures

Figure 1

Back to TopTop